HealthInvest Partners AB Makes New Investment in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)

HealthInvest Partners AB acquired a new position in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 125,000 shares of the company's stock, valued at approximately $1,201,000. Fusion Pharmaceuticals comprises 0.9% of HealthInvest Partners AB's investment portfolio, making the stock its 27th biggest holding. HealthInvest Partners AB owned about 0.17% of Fusion Pharmaceuticals as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Millennium Management LLC acquired a new stake in Fusion Pharmaceuticals during the 2nd quarter valued at approximately $29,000. Schonfeld Strategic Advisors LLC purchased a new stake in Fusion Pharmaceuticals in the first quarter valued at $49,000. Renaissance Technologies LLC acquired a new stake in Fusion Pharmaceuticals during the 3rd quarter worth about $51,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Fusion Pharmaceuticals during the 4th quarter valued at about $80,000. Finally, Citadel Advisors LLC acquired a new position in shares of Fusion Pharmaceuticals in the 3rd quarter valued at about $86,000. Institutional investors and hedge funds own 72.85% of the company's stock.

Fusion Pharmaceuticals Trading Down 0.1 %

NASDAQ FUSN traded down $0.02 during trading hours on Tuesday, reaching $21.26. The company had a trading volume of 550,862 shares, compared to its average volume of 2,104,842. The company has a current ratio of 15.01, a quick ratio of 15.01 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $1.80 billion, a P/E ratio of -14.48 and a beta of -0.73. The stock has a 50-day moving average of $15.28 and a 200 day moving average of $9.41. Fusion Pharmaceuticals Inc. has a 1-year low of $2.31 and a 1-year high of $21.55.

Fusion Pharmaceuticals (NASDAQ:FUSN - Get Free Report) last posted its quarterly earnings data on Wednesday, March 20th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.05). Fusion Pharmaceuticals had a negative net margin of 4,136.55% and a negative return on equity of 46.59%. As a group, research analysts anticipate that Fusion Pharmaceuticals Inc. will post -1.46 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on FUSN. Truist Financial reissued a "hold" rating and set a $21.00 price target (up from $11.00) on shares of Fusion Pharmaceuticals in a report on Tuesday, March 19th. Jefferies Financial Group reiterated a "hold" rating and set a $21.00 price target (up previously from $10.00) on shares of Fusion Pharmaceuticals in a research report on Tuesday, March 19th. William Blair cut Fusion Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research report on Tuesday, March 19th. Bloom Burton lowered Fusion Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Wednesday, March 20th. Finally, Brookline Capital Management lowered shares of Fusion Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday, March 19th. Thirteen analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $20.25.

Fusion Pharmaceuticals Company Profile

Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor.

Want to see what other hedge funds are holding FUSN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.